Clinical Trials Browser

Gastric Cancer With Liver Metastases

Breast Diseases, Breast Neoplasms

Adenocarcinoma, Rectal Neoplasms

Alzheimer Disease, Lymphoma, Follicular, Cognitive Dysfunction

SCLC, Limited Stage

Marijuana Abuse, Prostatic Neoplasms

Triple Negative Breast Neoplasms

Pancreatic Neoplasms

Advanced Breast Cancer

HER-2 Negative Breast Cancer

Carcinoma, Non-Small-Cell Lung

Urinary Bladder Neoplasms

Lymphoma, B-Cell, Marginal Zone

Stomatitis, Ulcer

Small Cell Lung Carcinoma

Peritoneal Neoplasms

Breast Neoplasms

Breast Neoplasms

Lymphoma, Follicular

Uterine Cervical Neoplasms

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

Carcinoma, Renal Cell

Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer With Liver Metastases

Breast Neoplasms

Neoplasms, Neuroendocrine Tumors

Carcinoma, Non-Small-Cell Lung

Adrenocortical Carcinoma

Carcinoma, Hepatocellular

Pancreatic Cancer Liver Metastases

Nasopharyngeal Carcinoma

Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Carcinoma, Non-Small-Cell Lung

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Patients With Advanced Solid Tumors Who Discontinued Treatment Due to irAE

Rectal Neoplasms

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Nasopharyngeal Carcinoma

Stomach Neoplasms

Breast Neoplasms

Lymphoma, Large B-Cell, Diffuse

Acrocephalosyndactylia

Stomach Neoplasms

Adenoma, Islet Cell, Neuroendocrine Tumors

Lymphoma, Follicular

Primary/Secondary Prevention

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Clinical Trials

TACE Combined With Thermal Ablation and ADC, PD-1, and Chemotherapy as First-line Treatment for HER2-highly-expressing Gastric Cancer With Liver Metastases: A Multicenter, Single-arm Prospective Clinical Study.

Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study

NOAHS-ARC

FEAD

A Multicenter, Randomized, Cohort, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Without Progression After Concurrent Chemoradiotherapy

ProCan

Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors：A Prospective Exploratory Study

2025-370

Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer

ASTEROID

IMGeS

VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

Copaíba-based Mouthwash in Oral Mucotitis Prevention and Treatment in Oral Cancer Patients During Radioteraphy

Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer

PrimPIPAC

A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Anti-tumor Treatment in Advanced Breast Cancer

Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases

ZR2 Versus R2 Regimen in the Treatment of Newly Diagnosed Follicular Lymphoma

SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer

Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC

SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma

Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer

SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases

Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast Cancer

TENET

the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib

ACCOMPLISH

Efficacy and Safety of Radiotherapy Combined With Tislelizumab and Anlotinib in the Treatment of Hepatocellular Carcinoma Complicated With Portal Vein Tumor Thrombus

NEOPRIME

A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With Arterial Infusion Chemotherapy and Embolization Combined With Dual Immune Checkpoint Inhibitors.

MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC

QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer

NOGA

Hybrid Dose-fraction Radiotherapy for Metastatic Non-small Cell Lung Cancer

Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer

Ivarmacitinib in Advanced Solid Tumors: A Prospective, Two-Cohort, Two-Phase Exploratory Study in Patients Discontinued Due to Immune Intolerance

SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC

Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC

Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer

A Clinical Study of Hetrombopag for Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal Carcinoma

Comparing the Safety and Efficacy of First-line Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions

Hetrombopag for the Prevention of ADC-Induced Thrombocytopenia in Breast Cancer: An Exploratory, Dual-Cohort, Phase 2 Study

R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma

NCCH2006/MK010 Trial (FORTUNE Trial)

Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer

Patients With High-grade Pancreatic Neuroendocrine Tumors

A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma (LTB-FL).

Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN

Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma